Ekaterina M. Kamenskih

Ekaterina M. Kamenskih

Auto-generated profile, based on publicly available information

Ekaterina M. Kamenskih

Siberian State Medical University

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2022 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
TST. S. Sokolova
T. S. Sokolova
EKE. M. Kamenskikh
E. M. Kamenskikh
DBD. V. Boguta
D. V. Boguta
YBYu. O. Bahareva
Yu. O. Bahareva
OFO. S. Fedorova
O. S. Fedorova
The development of biomedical research based on predictive, preventive and personalized medicine has served as a challenge to the formation and rapid development of a novel interdisciplinary scientific area — biobanking, the main goal of which is the long-term proper storage of biological samples and related data for use in scientific and clinical research. Qualified personnel, along with the creation and development of biobank infrastructure, provide high-quality results required for biomedicine. Education and training must reflect the changing scope of knowledge and adapt to biobanking challenges. In this regard, there is an increasing need to develop and implement educational programs for staff working in and managing biobanks, as well as researchers, doctors and students who are not familiar with this area, but plan research using bioresources. The aim of this review is to present an analysis of the main biobanking directions and training programs in the world and in Russia in order to assess the existing problems and needs.

10 December 2023 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
EKE. M. Kamenskikh
E. M. Kamenskikh
YBYu. O. Bakhareva
Yu. O. Bakhareva
YDYu. D. Demchenko
Yu. D. Demchenko
TST. S. Sokolova
T. S. Sokolova
SKStanislav Kazakov
Stanislav Kazakov
ЮБЮ. О. Бахарева
Ю. О. Бахарева
Aim. To assess awareness of biobanking among patients and healthcare professionals, and to identify factors influencing willingness to become donors and participate in the collection of biological material. Material and methods . A qualitative study was conducted based on semi-structured interviews of doctors (n=11) and patients (n=11) of Tomsk medical organizations. The results obtained were processed using lexical and comparative analysis techniques. Results. The experience of participation in biobanking was extremely limited among both patients and doctors, but those who had previous experience evaluated it positively. Patients and doctors had not received information about biobanks from official sources, but intuitively understood their functions and roles in biomedical research. Patients were willing to donate biomaterials, while doctors were willing to collect them, but both parties emphasized the importance of understanding the purpose and future use of the biomaterials. Patients wanted to ensure the safety of the collection procedures and the confidentiality of their personal data. The main motives for donating biomaterial were contribution to scientific development, potential attractiveness for the descendants of donors, social origin and material reward. Conclusion. Popularizing biobanking and increasing the awareness of donors and healthcare professionals about the regulatory framework governing biobanking activities can help establish trust and enhance readiness for donation, even regarding invasive biomaterial collection procedures.

1 January 2022 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
VAV.M. Alifirova
V.M. Alifirova
EKE.M. Kamenskikh
E.M. Kamenskikh
EKEkaterina Koroleva
Ekaterina Koroleva
EKE.V. Kolokolova
E.V. Kolokolova
APA.M. Petrakovich
A.M. Petrakovich
Рассеянный склероз (РС) — хроническое аутоиммуное заболевание, имеющее высокую степень гетерогенности по своему течению и прогнозу. Более половины пациентов с РС не обсуждают долгосрочный прогноз с лечащим врачом. При этом большинство пациентов считают крайне важным получение персонализированной информации о течении РС для принятия решений в отношении планирования семьи, выбора профессии, лечебных вмешательств. Для определения прогноза в рутинной клинической практике используются клинические маркеры, но номинально они делятся на благоприятный и неблагоприятный факторы, что позволяет сделать обобщенное заключение о прогнозе РС. Преимущественно в научных целях используются нейровизуализационные и биологические маркеры, которые уже активно применяются в клинических исследованиях для определения влияния терапии на органические причины стойкой инвалидизации. В обзоре описаны исследования по изучению прогностической ценности ряда клинических, нейровизуализационных и биологических маркеров.

23 January 2024 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
EKE.M. Kamenskikh
E.M. Kamenskikh
VAV.M. Alifirova
V.M. Alifirova
DPD.V. Pashkovskaya
D.V. Pashkovskaya
MTM.A. Titova
M.A. Titova
EKEkaterina Koroleva
Ekaterina Koroleva
SISvetlana Ivanova
Svetlana Ivanova
OBJECTIVE To study a role of serum neurofilament light chains (sNFL) in assessment of course and progression of multiple sclerosis (MS) in the population of patients with MS in the Tomsk region. MATERIAL AND METHODS The study involved 93 patients with relapsing-remitting MS (RRMS) and secondary progressive MS (SPMS) (nRRMS=75, nSPMS=18). The study was carried out in a two-stage design: the first stage was a cross-sectional study for the entire sample; the second stage was a prospective observation with two visits for patients with relapse. sNFL concentration was determined by solid-phase ELISA. RESULTS There was no statistically significant difference between RRMS and SPMS, and relapse and remission groups in terms of sNFL levels. Patients with a MS duration exceeding 14 years had higher rates of sNFL than those with a shorter duration (p=0.02). The subjects of the second study stage showed a decrease in sNFL from 2.05 (1.86; 2.19) pg/ml to 1.92 (1.87; 2.04) pg/ml (p=0.005), and slowdown in sNFL reduction correlated with the severity of cognitive impairment (k=0.52; p<0.05). CONCLUSION Dynamic monitoring of sNFL allows the evaluation of the activity of the disease, as well as making an assumption about the compensatory possibilities of subsequent recovery.

23 April 2024 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
YSYa.S. Shaglaeva
Ya.S. Shaglaeva
MTM.A. Titova
M.A. Titova
DPD.V. Pashkovskaya
D.V. Pashkovskaya
EKE.M. Kamenskikh
E.M. Kamenskikh
VAV.M. Alifirova
V.M. Alifirova
Adherence to therapy largely determines the success of treatment interventions: low levels of adherence are associated with reduced treatment effectiveness. For many chronic diseases, the level of adherence to treatment is about 50% or less, which confirms the relevance of this topic and requires its research. The high costs of treatment, the need for long-term continuous use of drugs and the special socio-economic significance of a disease such as multiple sclerosis (MS) determine the importance of maintaining a high level of adherence to its treatment. An analysis of literature data on the concept of treatment adherence, methods of its definition and influencing factors was carried out, the values of the level of adherence in the treatment of MS, as well as measures to maintain it during the COVID-19 pandemic were considered. Increasing awareness of healthcare professionals about the problem of treatment adherence and ways to improve it helps to improve the efficiency of managing patients with MS. The paper considers the primary stage of the strategy to improve treatment adherence among patients with MS, namely the formation of expanded knowledge of the problem by specialists of a multidisciplinary team involved in the diagnosis and treatment of patients with MS.

1 September 2022 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
KCK. A. Chubakova
K. A. Chubakova
EKE. M. Kamenskikh
E. M. Kamenskikh
YBYu. O. Bakhareva
Yu. O. Bakhareva
TSTatiana Saprina
Tatiana Saprina
ЮБЮ. О. Бахарева
Ю. О. Бахарева
Biobanking is an actively developing scientific area that provides tools for conducting biomedical research, increasing the reliability and reproducibility of their results. In endocrinology, more and more attention is paid to the study of molecular and genetic markers of diseases for the selection of new points of influence in treatment, the development of targeted therapy and a strategy for personalized prevention. This approach is designed to solve the problems of endocrine disorders, their complications, causing significant damage to the individual and he population health, and reduce the financial burden of chronic endocrine disorders. To increase the reliability and reproducibility of research results, requirements for working with biological material should be strictly complied. The use of biobanking will increase the validity of data obtained in clinical trials in endocrinology. There are successful examples of Russian and foreign studies using the capabilities of biobanks aimed at studying diabetes, polycystic ovary syndrome, adenomas and other endocrine disorders. The article discusses the prospects for partnership with biobanks in the framework of endocrinology research. The purpose of this review is to analyze the literature to systematize knowledge for application of biobanking in biomedical research in the field of endocrinology.